Mark Corrigan
Board
Nabriva Therapeutics
Austria
Biography
He is former President and Chief Executive Officer of Zalicus, Inc. Previously, He was Executive Vice President of Research and Development at the specialty pharmaceutical company Sepracor Inc., and prior to this, he spent 10 years with Pharmacia & Upjohn, most recently as Group Vice President of Global Clinical Research and Experimental Medicine. Before entering the healthcare industry,He was in academic research at the University of North Carolina at Chapel Hill School of Medicine, where he maintains a faculty appointment as Adjunct Professor in the Psychiatry Department.He served on the Board of Directors for Cubist Pharmaceuticals and of Avanir Pharmaceuticals prior to their acquisitions by Merck and Otsuka Holdings, respectively, and served as chairman of EPIRUS Biopharmaceuticals’ Board. He holds an M.D. degree from the University of Virginia and received specialty training in psychiatry at Maine Medical Center and Cornell University. He is former President and Chief Executive Officer of Zalicus, Inc. Previously, He was Executive Vice President of Research and Development at the specialty pharmaceutical company Sepracor Inc., and prior to this, he spent 10 years with Pharmacia & Upjohn, most recently as Group Vice President of Global Clinical Research and Experimental Medicine. Before entering the healthcare industry,He was in academic research at the University of North Carolina at Chapel Hill School of Medicine, where he maintains a faculty appointment as Adjunct Professor in the Psychiatry Department.He served on the Board of Directors for Cubist Pharmaceuticals and of Avanir Pharmaceuticals prior to their acquisitions by Merck and Otsuka Holdings, respectively, and served as chairman of EPIRUS Biopharmaceuticals’ Board. He holds an M.D. degree from the University of Virginia and received specialty training in psychiatry at Maine Medical Center and Cornell University.
Research Interest
Pharmacology.
